Latest News for: bristol myers squibb

Edit

IHL elects new Board VP, approves new degree paths

Delta Democrat-Times 24 Jan 2025
The Board also approved a Miss ... One was to enter into an agreement with Bristol-Myers Squibb Company to purchase autologous cell therapy products that can alter T-cells and subsequently provide patients with an immunological response to cancer ... .
Edit

Eosinophilic Esophagitis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights ...

GetNews 24 Jan 2025
Key companies developing therapies for Eosinophilic Esophagitis are - Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, NexEos Diagnostics, Inc., Celgene, and others ... 1 ... 2.
Edit

Lung Transplant Rejection Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight ...

GetNews 23 Jan 2025
Lung Transplant Rejection companies working in the treatment market are Corline Biomedical, MimeTech, TFF Pharmaceuticals, Kamada, Genentech, Bristol Myers Squibb, and others, are developing therapies for the Lung Transplant Rejection treatment.
Edit

Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress ...

GetNews 23 Jan 2025
Key companies developing therapies for Non Muscle Invasive Bladder Cancer are - Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers ...
Edit

You Were Diagnosed with Advanced Kidney Cancer. Now What?

The Call 23 Jan 2025
Indication ... Call 1-800-FDA-1088 ... Bristol-Myers Squibb at 1- 844-593-7869 as soon as you become aware of a pregnancy ... © 2025 Bristol-Myers Squibb Company. OPDIVO®, YERVOY® and the related logos are registered trademarks of Bristol-Myers Squibb Company.
Edit

Interstitial Lung Disease Therapeutics Market Size in the 7MM is anticipated to increase by 2032 ...

GetNews 22 Jan 2025
... Boehringer Ingelheim, GlaxoSmithKline, Insmed Incorporated, United Therapeutics, Liquidia Technologies, Inc., Bristol-Myers Squibb, aTyr Pharma, Inc., AstraZeneca, and others ... Bristol Myers Squibb.
Edit

Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios ...

GetNews 22 Jan 2025
... Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others ... Bristol-Myers Squibb.
Edit

These NJ companies made Newsweek's list of most trustworthy in the U.S.

New Jersey Herald 22 Jan 2025
NJ 2025 State of the State. Phil Murphy on economy/innovation centers. New Jersey Gov. Phil Murphy gave his final State of the State address ... Food and beverage ... Princeton’s Bristol Myers Squibb ranked 28th, while Kenilworth-based Merck & Co ... Retail.
Edit

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva� in China as Second-line Treatment

Antara News 22 Jan 2025
References. 1. Sehn LH, Salles G ... 2 ... Carteyva�) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company) ... Source.
Edit

KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, ...

GetNews 22 Jan 2025
In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the ...
Edit

Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is ...

GetNews 21 Jan 2025
In January 2025.- Bristol-Myers Squibb- The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to ... Bristol Myers Squibb.
Edit

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

Pharmiweb 21 Jan 2025
  ... Aled’s remit will include creating partnership opportunities for the Aravax portfolio as well as evolving the platform and asset strategy ... Prior to Shire, Aled held senior roles at Bristol Myers-Squibb, Novartis and Hoffman-La Roche.  ... .
Edit

Psoriasis Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | ...

GetNews 21 Jan 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market ... In December 2024, Bristol Myers Squibb (NYSE ... In March 2024, Alumis Inc ... Psoriasis Overview.

Most Viewed

×